{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:23:43Z","timestamp":1792268623515,"version":"4.4.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated substantial improvements in patients with active ankylosing spondylitis (AS). This\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis evaluated the effects of ivarmacitinib on various dimensions of patient-reported outcomes (PROs) in active AS patients, utilizing data from a phase II\/III clinical trial (NCT04481139).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were assigned to receive either ivarmacitinib 4\u00a0mg (n = 187) or placebo (n = 186) daily for 12 weeks. Patients receiving placebo switched to ivarmacitinib thereafter until week 24. PROs included total back pain and night pain by visual analog scale (VAS), morning stiffness, Patient Global Assessment of Disease Activity (PtGA), AS Quality of Life (ASQol), 36-Item Short Form Health Survey (SF-36), Bath AS Disease Activity Index (BASDAI), and Bath AS Functional Index (BASFI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ivarmacitinib group showed significantly improvement in total back pain VAS (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), night pain VAS (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), morning stiffness (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), PtGA (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), ASQoL (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.034), and BASDAI (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) scores compared with placebo after 12 weeks of treatment. However, no significant between-group differences were observed for SF-36 physical scores (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.216), mental (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.105) component scores and BASFI score (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.744) at week 12. By week 24, all PROs were continuously improved in the ivarmacitinib group; patients who switched from placebo to ivarmacitinib 4\u00a0mg achieved substantial improvements in all PROs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ivarmacitinib significantly enhances multiple dimensions of PROs in active AS patients, supporting its utility in managing PROs in AS. Switching to ivarmacitinib also provides substantial benefits, this indicates that initiating ivarmacitinib treatment, even after an initial period of placebo leads to meaningful improvements in PROs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1710434","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:20:16Z","timestamp":1763619616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II\/III trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e52559","DOI":"10.7759\/cureus.52559","article-title":"Diagnosis and treatment of ankylosing spondylitis","volume":"16","author":"Agrawal","year":"2024","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"rkae141","DOI":"10.1093\/rap\/rkae141","article-title":"Rationale and concerns for using JAK inhibitors in axial spondyloarthritis","volume":"8","author":"Ahmed","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13075-023-03027-5","article-title":"Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies","volume":"25","author":"Baraliakos","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with Moderate-to-Severe, active, ulcerative colitis: a phase II study","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/bor.0000000000001020","article-title":"Axial spondyloarthritis guidelines - aiming for maximum impact","volume":"36","author":"Choufani","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1111\/1756-185x.14853","article-title":"Safety and efficacy of pharmacological treatments for axial spondyloarthritis","volume":"26","author":"Dong","year":"2023","journal-title":"Int. J. rheumatic Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.18502\/jovr.v16i3.9440","article-title":"Ankylosing spondylitis","volume":"16","author":"Ebrahimiadib","year":"2021","journal-title":"J. Ophthalmic Vis. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13102-022-00577-0","article-title":"The effect of aqua stretching exercises and pilates on pain, function and spine posture in patients with ankylosing spondylitis: a randomized controlled trial","volume":"14","author":"Gandomi","year":"2022","journal-title":"BMC Sports Sci. Med. Rehabil"},{"key":"B11","volume-title":"A study to evaluate the efficacy and safety of SHR0302 in patients with ankylosing spondylitis","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/acr.25111","article-title":"Responsiveness and minimum clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis: a prospective cohort study","volume":"75","author":"Karmacharya","year":"2023","journal-title":"Arthritis Care Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10922","DOI":"10.3390\/ijms222010922","article-title":"Cytokine networks in the pathogenesis of rheumatoid arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3899\/jrheum.090449","article-title":"Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"37","author":"Kvamme","year":"2010","journal-title":"J. Rheumatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2050312116671725","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: scoping review","volume":"4","author":"Lins","year":"2016","journal-title":"SAGE Open Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e70285","DOI":"10.1111\/1756-185x.70285","article-title":"Clinical response to adalimumab therapy and its determinants in patients with radiographic axial spondyloarthritis: a prospective real-world study in Taiwan","volume":"28","author":"Liu","year":"","journal-title":"Int. J. Rheumatic Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard-2024-226385","article-title":"Ivarmacitinib, a selective janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial","volume":"84","author":"Liu","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/art.43238","article-title":"Efficacy and safety of ivarmacitinib, a selective JAK1 inhibitor, in patients with active ankylosing spondylitis: results from an adaptive seamless phase 2\/3 trial","volume":"77","author":"Liu","year":"","journal-title":"Arthritis Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acr.25267","article-title":"Relationships of work productivity and activity impairment with patient-reported outcomes in ankylosing spondylitis: results from two trials","volume":"76","author":"Magrey","year":"2024","journal-title":"Arthritis Care Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41584-021-00625-y","article-title":"Ankylosing spondylitis: an autoimmune or autoinflammatory disease?","volume":"17","author":"Mauro","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e002049","DOI":"10.1136\/rmdopen-2021-002049","article-title":"Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e002253","DOI":"10.1136\/rmdopen-2022-002253","article-title":"Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Navarro-Comp\u00e1n","year":"2022","journal-title":"RMD Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s40744-023-00536-2","article-title":"Effect of upadacitinib on disease activity, pain, fatigue, function, health-related quality of life and work productivity for biologic refractory ankylosing spondylitis","volume":"10","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13075-024-03313-w","article-title":"Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis","volume":"26","author":"Navarro-Comp\u00e1n","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.rdc.2016.01.011","article-title":"Patient-reported outcomes in axial spondyloarthritis","volume":"42","author":"Nhan","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"B26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11882-014-0489-6","article-title":"Update on ankylosing spondylitis: current concepts in pathogenesis","volume":"15","author":"Smith","year":"2015","journal-title":"Curr. Allergy Asthma Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/art.38291","article-title":"Review: the interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/s0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/s0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 update of the American college of rheumatology\/spondylitis association of america\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3760\/cma.j.cn112138-20200505-00448","article-title":"Practice guideline for patients with ankylosing spondylitis\/spondyloarthritis","volume":"59","author":"Xie","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B36","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2025.0982","article-title":"Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial","volume":"161","author":"Zhao","year":"2025","journal-title":"JAMA Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00296-024-05615-3","article-title":"Diagnosis, monitoring, and management of axial spondyloarthritis","volume":"44","author":"Zimba","year":"2024","journal-title":"Rheumatol. Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/acr.20575","article-title":"Measures of symptoms and disease status in ankylosing spondylitis: ankylosing spondylitis disease activity score (ASDAS), ankylosing spondylitis quality of life scale (ASQoL), Bath ankylosing spondylitis disease activity index (BASDAI), bath ankylosing spondylitis functional index (BASFI), Bath ankylosing spondylitis global score (BAS-G), bath ankylosing spondylitis metrology index (BASMI), dougados functional index (DFI), and health assessment questionnaire for the spondylarthropathies (HAQ-S)","volume":"63","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1710434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:20:18Z","timestamp":1763619618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1710434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":38,"alternative-id":["10.3389\/fphar.2025.1710434"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1710434","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1710434"}}